CLASS II Drug recall · Reported 18 Mar 2020 · FDA Enforcement Report
Daptomycin, 500MG in 0.9% NACL Injectable Redline Specialty recalled
Redline Pharmacy Solutions is recalling Daptomycin, 500MG in 0.9% NACL Injectable Redline Specialty Pharmacy, 2415 Osborne Drive, distributed in Nebraska. The recall was initiated on 24 Feb 2020 and the FDA has classified it as Class II.
Check your package
Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.
Recall details
- Recall number
- D-1008-2020
- FDA event ID
- 85081
- Recalling firm
- Redline Pharmacy Solutions, Hastings, NE
- Classification
- Class II
- Status
- Terminated
- Recall initiated
- 24 Feb 2020
- FDA classified
- 12 Mar 2020
- Reported
- 18 Mar 2020
- Type
- Voluntary: Firm initiated
- Customers notified by
- Telephone
- Reason category
- Other Reasons
- Drug class
- Injectable & IV Drugs
Timeline
| 24 Feb 2020 | Recall initiated by company | |
| 12 Mar 2020 | Classified by FDA | +17 days |
| 18 Mar 2020 | Published in enforcement report | +6 days |
Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.
Reason for recall
Lack Of Processing Controls
Product as listed by the FDA
Daptomycin, 500MG in 0.9% NACL 100ML Injectable Redline Specialty Pharmacy, 2415 Osborne Drive E, #100 Hastings, NE 68901
Where it was distributed
Sold to patients in Nebraska
Questions about this recall
Why was it recalled?
Lack Of Processing Controls
Which lots are affected?
Lots 02242020@3, 02242020@9
Where was it sold?
Sold to patients in Nebraska
What should I do if I have it?
Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.
What does Class II mean?
Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.
Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.
Other products in this recall event
5 other products · FDA event 85081| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| CLASS II | Morphine Sulfate, 20 mg/mL intrathecal per syringe recalled | Redline Pharmacy Solutions | Other | NE | |
| CLASS II | Morphine Sulfate (Mitigo), 5 mg/mL intrathecal per syringe recalled | Redline Pharmacy Solutions | Other | NE | |
| CLASS II | Vancomycin 900MG in 0.9% NACL Injectable recalled | Redline Pharmacy Solutions | Other | NE | |
| CLASS II | Acetylcysteine Ophthalmic 10% Solution per dropper recalled | Redline Pharmacy Solutions | Other | NE | |
| CLASS II | Ertapenem in 0.9% NACL 1GM Injectable recalled | Redline Pharmacy Solutions | Other | NE |
More recalls from Redline Pharmacy Solutions
All 6| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| Drug | CLASS II | Ertapenem in 0.9% NACL 1GM Injectable recalled | Redline Pharmacy Solutions | Other | NE |
| Drug | CLASS II | Acetylcysteine Ophthalmic 10% Solution per dropper recalled | Redline Pharmacy Solutions | Other | NE |
| Drug | CLASS II | Vancomycin 900MG in 0.9% NACL Injectable recalled | Redline Pharmacy Solutions | Other | NE |
| Drug | CLASS II | Morphine Sulfate (Mitigo), 5 mg/mL intrathecal per syringe recalled | Redline Pharmacy Solutions | Other | NE |
| Drug | CLASS II | Morphine Sulfate, 20 mg/mL intrathecal per syringe recalled | Redline Pharmacy Solutions | Other | NE |
Other Daptomycin recalls
All 9| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| Drug | CLASS II | Daptomycin, in 0.9% Sodium Chloride Injection, 500 mg recalled | Baxter Healthcare | Manufacturing (CGMP) Deviations | Nationwide |
| Drug | CLASS II | Daptomycin, in 0.9% Sodium Chloride Injection, 1,000 mg recalled | Baxter Healthcare | Manufacturing (CGMP) Deviations | Nationwide |
| Drug | CLASS II | Daptomycin for Injection 350 mg/vial recalled by Accord HealthcareDaptomycin | Accord Healthcare | Manufacturing (CGMP) Deviations | PR |
| Drug | CLASS II | Daptomycin for Injection 500 mg per vial, Single-dose vial recalledDaptomycin | Accord Healthcare | Manufacturing (CGMP) Deviations | PR |
| Drug | CLASS I | Daptomycin for Injection 350 mg/vial-dose vial recalled | Accord Healthcare | Packaging Defects | Nationwide |